Structural investigations into the binding mode of a novel noscapine analogue, 9-(4-vinylphenyl) noscapine, with tubulin by biochemical analyses and molecular dynamic simulations

Mechanism of action of ixabepilone and its interactions with the βIII-tubulin isotype

(2015) Manu Lopus et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Biochemical characterization and molecular dynamic simulation of β-sitosterol as a tubulin-binding anticancer agent

(2015) Tejashree Mahaddalkar et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Taking aim at a dynamic target: Noscapinoids as microtubule-targeted cancer therapeutics

(2015) Manu Lopus et al.   Pharmacological Reports

The tubulin code: Molecular components, readout mechanisms, and functions

(2014) Carsten Janke   JOURNAL OF CELL BIOLOGY

Molecular insight of isotypes specific β-tubulin interaction of tubulin heterodimer with noscapinoids

(2014) Seneha Santoshi et al.   JOURNAL OF COMPUTER-AIDED MOLECULAR DESIGN

Rational design of biaryl pharmacophore inserted noscapine derivatives as potent tubulin binding anticancer agents

(2014) Seneha Santoshi et al.   JOURNAL OF COMPUTER-AIDED MOLECULAR DESIGN

Molecular modelling and competition binding study of Br-noscapine and colchicine provide insight into noscapinoid–tubulin binding site

(2011) Pradeep K. Naik et al.   JOURNAL OF MOLECULAR GRAPHICS & MODELLING

Antitumor Activity of Noscapine in Combination with Doxorubicin in Triple Negative Breast Cancer

(2011) Mahavir B. Chougule et al.   PLoS One

Griseofulvin stabilizes microtubule dynamics, activates p53 and inhibits the proliferation of MCF-7 cells synergistically with vinblastine

(2010) Krishnan Rathinasamy et al.   BMC CANCER

In vivo efficacy of griseofulvin against multiple myeloma

(2010) Young Kim et al.   LEUKEMIA RESEARCH

Quantitative analysis of the effect of tubulin isotype expression on sensitivity of cancer cell lines to a set of novel colchicine derivatives

(2010) Chih-Yuan Tseng et al.   Molecular Cancer

Novel C-seco-taxoids possessing high potency against paclitaxel-resistant cancer cell lines overexpressing class III β-tubulin

(2009) Antonella Pepe et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Class III β-tubulin expression and in vitro resistance to microtubule targeting agents

(2009) C Stengel et al.   BRITISH JOURNAL OF CANCER